Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Sep;51(9):1107-1120.
doi: 10.1111/cea.13997. Epub 2021 Aug 12.

Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19

Collaborators, Affiliations
Clinical Trial

Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19

Daniel Munblit et al. Clin Exp Allergy. 2021 Sep.

Abstract

Background: The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors.

Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire.

Results: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32).

Conclusions: Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.

Keywords: COVID-19; PASC; asthma; long COVID; post-COVID Condition; post-COVID Syndrome; postacute sequelae SARS-CoV-2 infection; risk factors.

PubMed Disclaimer

Conflict of interest statement

J. Genuneit reports working as a project manager of unrestricted research grants on the composition of breast milk to the Ulm University and Leipzig University. M.G. Semple reports grants from DHSC National Institute of Health Research UK, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool outside the submitted work; he also reports a minority ownership at Integrum Scientific LLC, Greensboro, NC, USA outside the submitted work. T. Vos reports personal fees for work on Global Burden of Disease Study from Bill and Melinda Gates Foundation, outside the submitted work. All other authors report no relevant conflict of interests.

Figures

FIGURE 1
FIGURE 1
Flow diagram of patients with COVID‐19 admitted to Sechenov University Hospital Network between April 8 and July 10, 2020. PCR, polymerase chain reaction
FIGURE 2
FIGURE 2
Venn plot presenting coexistence of (A) five most common persistent symptoms and (B) five most common categories of persistent symptoms at the time of the follow‐up interview
FIGURE 3
FIGURE 3
Multivariable logistic regression model. Odds ratios and 95% CIs for “Neurological” category of persistent symptoms at the time of follow‐up. Abbreviation: CI, confidence interval. (A) primary analysis (age, sex, comorbidities, severity and RT‐PCR were included as potential risk factors); (B) sensitivity analysis (performed in a subgroup of RT‐PCR positive patients only)
FIGURE 4
FIGURE 4
Multivariable logistic regression model. Odds ratios and 95% CIs for “Mood and behaviour” category of persistent symptoms at the time of follow‐up. Abbreviation: CI, confidence interval. (A) primary analysis (age, sex, comorbidities, severity and RT‐PCR were included as potential risk factors); (B) sensitivity analysis (performed in a subgroup of RT‐PCR positive patients only)
FIGURE 5
FIGURE 5
Multivariable logistic regression model. Odds ratios and 95% CIs for “Chronic fatigue” category of persistent symptoms at the time of follow‐up. Abbreviation: CI, confidence interval. (A) primary analysis (age, sex, comorbidities, severity and RT‐PCR were included as potential risk factors); (B) sensitivity analysis (performed in a subgroup of RT‐PCR positive patients only)

References

    1. Dong E, Du H, Gardner L. An interactive web‐based dashboard to track COVID‐19 in real time. Lancet Infect Dis. 2020;20(5):533‐534. - PMC - PubMed
    1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid‐19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. - PMC - PubMed
    1. Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: an observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID‐19 infection. Clin Infect Dis. 2020;73(1):1‐11. 10.1093/cid/ciaa1535 - DOI - PMC - PubMed
    1. Pritchard MG. COVID‐19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. medRxiv. 2020:2020.2010.2026.20219519. - PubMed
    1. Carfi A, Bernabei R, Landi F. Gemelli against C‐P‐ACSG. persistent symptoms in patients after acute COVID‐19. JAMA. 2020;324(6):603‐605. - PMC - PubMed